PRDM1
PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection. Binds specifically to the PRDI element in the promoter of the beta-interferon gene. Drives the maturation of B-lymphocytes into Ig secreting cells. Associates with the transcriptional repressor ZNF683 to chromatin at gene promoter regions. Binds to the promoter and acts as a transcriptional repressor of IRF8, thereby promotes transcription of osteoclast differentiation factors such as NFATC1 and EEIG1. Location: Nucleus; Cytoplasm (UniProt). Locus 6q21 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.62 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (NHL)
- Multiple myeloma: IntOGen driver in 2 cohorts (PCM)
- Prostate cancer: IntOGen driver in 1 cohort (PROSTATE)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Ovarian cancer: Open Targets association 0.50 with ovarian cancer (MONDO_0008170)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"PRDM1" OR ABSTRACT:"PRDM1" OR TITLE:"PR/SET domain 1" OR ABSTRACT:"PR/SET domain 1" OR TITLE:"PR domain zinc finger protein 1" OR ABSTRACT:"PR domain zinc finger protein 1" OR TITLE:"PRDI-BF1" OR ABSTRACT:"PRDI-BF1" OR TITLE:"Blimp-1" OR ABSTRACT:"Blimp-1" OR TITLE:"BLIMP1" OR ABSTRACT:"BLIMP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRDM1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/prdm1.json. Licence CC BY-NC 4.0.